AIM: Clinical trials have shown prophylactic human papillomavirus (HPV) vaccines to be
effective against infection and disease. We examined whether HPV vaccination has the …

Background: A vaccine against human papillomavirus (HPV) types 6, 11, 16 and 18 is now
licensed for use in Canada and many other countries. We sought to estimate the number …

Introduction: Human papillomavirus (HPV) is one of the world's most common sexually
transmitted infections, and has been associated with a number of cervical and non-cervical …

Since 2006, 115 countries and territories have introduced human papillomavirus (HPV)
vaccination programs. Several efforts have been undertaken to evaluate the impact of HPV …

Background Human papillomavirus (HPV) vaccines are widely available and there have
been studies exploring their potential clinical impact and cost-effectiveness. However, few …

It has been estimated that genital human papillomavirus (HPV) is the most common sexually
transmitted infection in the US. Nononcogenic types, such as HPV type 6 (HPV‐6) and HPV …

Background The cost-effectiveness of prophylactic vaccination against human
papillomavirus types 16 (HPV-16) and 18 (HPV-18) is an important consideration for …

Objective The goal of this study was to review the current human papillomavirus (HPV)
vaccine program and its outcomes to date in Australia. Methods This was a review of the …

Human papillomavirus (HPV) infection, usually a sexually transmitted disease, is a risk factor
for cervical cancer. Given the substantial disease and death associated with HPV and …

Ten years after the first licencing of a prophylactic human papillomavirus (HPV) vaccine, this
paper reviews global information on programme coverage, as reported to WHO and from the …